JHL Biotech's Final Trading Day on Taipei Exchange
HSINCHU and WUHAN, China, Feb. 12, 2018 /PRNewswire/ -- JHL Biotech
JHL Biotech's Application to Voluntarily Terminate Trading of Shares Approved by Taipei Exchange
HSINCHU, and WUHAN, China, Feb. 5, 2018 /PRNewswire/ -- JHL Biotech
JHL Biotech Shareholders Vote to Voluntarily Delist from Taiwan Exchange
HSINCHU and WUHAN, Feb. 1, 2018 /PRNewswire/ -- JHL Biotech
JHL Biotech Welcomes New Chief Medical Officer, Rong Chen
HSINCHU and WUHAN, China, Jan. 2, 2018 /PRNewswire/ -- JHL Biotech
JHL Biotech Submits Clinical Trial Application in Europe for Proposed Dornase Alfa Biosimilar to Affordably Manage Symptoms of Cystic Fibrosis
HSINCHU, Taiwan and WUHAN, mainland China, Dec. 21, 2017 /PRNewswire/ -- JHL
Biotech
JHL Biotech Submits Clinical Trial Application in Europe for Proposed Bevacizumab Biosimilar to Treat Colorectal, Lung, and Ovarian Cancers
HSINCHU, Taiwan and WUHAN, China, Dec. 20, 2017 /PRNewswire/ -- JHL Biotech Inc.
JHL Biotech and Affinita Biotech Agree to Partner in the Development and Manufacturing of Oncology Monoclonal Antibodies
HSINCHU, , March 1, 2016 /PRNewswire/ -- JHL Biotech, Inc. (Stock Code: 6540.TWO) announced it has entered into a contract manufacturing master service agreement with Affinita Biotech. The agreement covers a development and manufacturing partnership for Affinita's oncology monoclonal antibodies. ...
JHL Biotech Receives Approval From European Authorities to Begin Biosimilar Clinical Trial
HSINCHU, , Feb. 15, 2016 /PRNewswire/ -- JHL Biotech, Inc. (Stock Code: 6540.TWO) announced it has received authorization from theUnited Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) to begin clinical trial for JHL1101, a rituximab biosimilar developed and manufactured ...
JHL Biotech Appoints New Leaders to Management Team
HSINCHU, Oct. 20, 2015 /PRNewswire/ -- JHL Biotech
JHL Biotech Lists on the Taiwan Emerging Stock Board
HSINCHU, Oct. 3, 2015 /PRNewswire/ -- JHL Biotech
